Bristol-Myers Squibb Co (NYSE: BMY) shares spiked 4.5 percent Tuesday on news that Carl Icahn bought a stake in the company. According to the Wall Street Journal, Icahn allegedly considers Bristol-Myers a potential takeover target.
Earlier Tuesday, Bristol-Myers reported a $2 billion accelerated buyback.
The investor's expectation corroborates a January Bloomberg report acknowledging Bristol-Myers' fall from the fourth-best to the ninth-best biopharmaceutical company in the US. The company’s struggle to push its lung cancer drug, Opdivo, set it well behind competitor Merck & Co., Inc. (NYSE: MRK) and prompted a two-year plunge in stock value.
Now, as a more affordable company with a promising blood thinner and a potential use for Opdivo in melanoma and kidney cancer treatments, Bristol-Myers is well positioned for a buyout.
Related Link: Here's What Merck's Keytruda News Means For Bristol-Myers
Jefferies analyst Jeffrey Holford suggested in a recent note the company may appeal to Sanofi SA (ADR) (NYSE: SNY), Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE) and Novartis AG (ADR) (NYSE: NVS) — but not likely Amgen, Inc. (NASDAQ: AMGN) or Gilead Science, Inc. (NASDAQ: GILD).
Meanwhile, Deutsche Bank analysts proposed Pfizer would likely be deterred by the short-term risk of immuno-oncology trials and wouldn't make a bid.
Bristol-Myers stock waned from its post-news peak and traded at $54.78 at the time of publication.
See more from Benzinga
- Advanced Micro Devices Establishes New 2017 High As New Ryzen Processors To Ship Next Week
- When Will Taser's Impressive Revenue Growth Translate To The Bottom Line?
- T-Mobile Continues To Gobble Up Market Share, Now 3rd Place In The U.S.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.